Drugs / TAVOLIMAB
TAVOLIMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02705482 | Mar 2016 → Aug 2019 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02318394 | Mar 2015 → Jan 2018 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03267589 | May 2018 → Oct 2021 | ovarian cancer | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03336606 Comparator | Jul 2018 → Jun 2025 | head and neck squamous cell carcinoma, melanoma | Providence Health & Services | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAVOLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298028 ↗ |
| Known as | MEDI0562 | “Intervention: MEDI0562 (OX40) + durvalumab” NCT03267589 ↗ |
| Known as | Tavolixizumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298028 ↗ |
| Action | Activate | “MEDI0562, an agonistic humanized mAb, specifically binds to the costimulatory molecule OX40.” PMID 32816951 ↗ Aug 2020 |
| Modality | Monoclonal antibody | “MEDI0562, an agonistic humanized mAb, specifically binds to the costimulatory molecule OX40.” PMID 32816951 ↗ Aug 2020 |
| Route | Intravenous | “every 4 weeks, intravenously” PMID 35699623 ↗ Sep 2022 |